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Individuals Are Sites of HCMV Reactivation In
Vivo
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Human cytomegalovirus (HCMV) causes signiﬁcant morbidity in the immunocompromised host. Following pri-
mary infection, the virus establishes latent infection in progenitor cells of the myeloid lineage. These cells exhibit
limited viral gene transcription and no evidence of de novo virion production. It is well recognized that differen-
tiation of latently infected myeloid progenitor cells to dendritic or macrophage-like cells permits viral reactivation
in vitro. This has been used to support the concept that viral reactivation in HCMV carriers routinely occurs from
such terminally differentiated myeloid cells in vivo. However, to date this has not been shown for in vivo–
differentiated macrophages. This study is the ﬁrst to demonstrate that alveolar macrophages fromHCMV carriers
express immediate early lytic genes and produce infectious virus. This supports the view, until now based on in
vitro data, that terminally differentiated myeloid cells in vivo are sites of HCMV reactivation and potential centers
of viral dissemination in latently infected individuals with no evidence of virus disease or dissemination.
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Human cytomegalovirus (HCMV) has the largest
genome among human herpesvirus, and, like all herpes-
viruses, it has 2 different life cycles. The lytic life cycle
occurs in terminally differentiated cells such as ﬁbro-
blasts, dendritic cells (DCs), and endothelial cells and
commences with immediate early (IE) gene expression,
followed by early gene expression and late gene expres-
sion. This culminates in viral production over a 72-hour
period, as observed in primary ﬁbroblasts in culture [1].
Primary HCMV infection of immunocompetent indi-
viduals rarely results in serious disease. Despite a robust
immune response, HCMV is not eradicated in these
individuals, as the virus enters a latent phase of in-
fection [2–4]. Cells of the myeloid lineage, such as
CD34+ progenitor cells and their CD14+ monocyte de-
rivatives, are well-characterized sites of HCMV latency
in healthy seropositive carriers. Differentiation of these
naturally latently infected myeloid cells ex vivo into ter-
minally differentiated DCs leads to reactivation of the
viral lytic transcription program and virion production
[2–6]. Similarly, this differentiation-dependent reactiva-
tion of latent virus can also be fully recapitulated in a
number of experimental models of HCMV latency in
CD34+ or CD14+ cells infected in vitro [7–11]. Collec-
tively, these observations of the lytic and latent life cy-
cles of HCMV in the myeloid lineage underscore the
close link between myeloid differentiation and virus re-
activation from latency and predict that reactivation of
the viral lytic transcription program should occur rou-
tinely in terminally differentiated myeloid cells in vivo.
Consistent with this, recent work has shown that imma-
ture DCs taken directly from the blood of HCMV-sero-
positive individuals are positive for viral IE gene
expression and reactivate full virus production under
additional inﬂammatory stimuli ex vivo [12].
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In addition to their differentiation into DCs, the differentia-
tion of monocytes into monocyte-derived-macrophage (MDM)
cell lines ex vivo produces cells that are permissive to HCMV
infection [13–15]. Additionally, reactivation of lytic gene ex-
pression from latently infected myeloid cells differentiated ex
vivo into MDMs has also been demonstrated [16, 17], but
whether macrophages differentiated in vivo (eg, alveolar macro-
phages) are also sites of virus reactivation has never previously
been addressed.
HCMV pneumonitis with virus detectable in bronchoalveo-
lar lavage (BAL) can occur after both solid organ and bone mar-
row transplantations [18], and this has suggested that the lung
may be a normal site of reactivation in healthy carriers in vivo,
which, in the transplant recipient, cannot be limited by the nor-
mal host immune response due to recipient immunosuppres-
sion. We are the ﬁrst to show that macrophages differentiated
in vivo (ie, alveolar macrophages) are sites of reactivation of
HCMV in virus carriers in the absence of HCMV disease or
inﬂammation. Collectively, these data argue that the differenti-
ation of myeloid precursor cells in vivo into alveolar macr-
ophages promotes the reactivation of HCMV lytic gene
expression in individuals who are not viremic for HCMV dis-
ease and helps conﬁrm ﬁndings from studies performed on
HCMV reactivation that used ex vivo generation of macrophag-
es from myeloid precursors.
METHODS AND METHODS
Ethics Statement
All human studies were approved by the local research ethics com-
mittee and complied with the Declaration of Helsinki. Written in-
formed consent to collect blood and to retain BAL ﬂuid (BALF)
was obtained from patients undergoing ﬁber-optic bronchoscopy
(ethical approval UK08/H0306/17 and UK06/Q0108/281).
Isolation and Puriﬁcation of Alveolar Macrophages From BALF
BALF was obtained from routine bronchoscopies for nonin-
ﬂammatory/noninfectious disorders, with the BAL taken from
radiologically normal lobes. The ﬁber-optic bronchoscopy was
wedged into the subsegmental bronchus in an area contralateral
to the side of any radiological change observed on the chest ra-
diograph or computed tomogram. A total of 150 mL of sterile
isotonic saline was instilled in 50-mL aliquots with gentle suc-
tioning after each aliquot. BALF recovery averaged 90 mL
(60%), with a range of 50 to 120 mL. The retrieved BALF was
immediately placed on ice and processed within 15 minutes by
ﬁltering through sterile gauze to remove mucus. The BALF was
centrifuged at 300g at 4°C for 7 minutes, and the cell pellet was
washed twice in 40 mL of phosphate-buffered saline with calci-
um and magnesium and resuspended at 5 × 105 cells/mL in
X-vivo-15 (Lonza) supplemented with 1:100 Gibco Antibiotic-
Antimycotic (containing penicillin 10 000 U/mL, streptomycin
10 000 U/mL, and 25 μg/mL amphotericin B from Life Tech-
nologies15 240 062). The differential leukocyte count of the
BALF was determined by light microscopy of cytospins stained
with modiﬁed Wright stain (WS16; Sigma-Aldrich). The cells
isolated from the BALF were cytocentrifuged for 3 minutes at
300g onto Polysine microscope slides (VWR International),
using a Shandon Cytospin 2 (Shandon, United Kingdom).
Alveolar macrophages were identiﬁed by their large dark nuclei
and abundant pale, granular cytoplasm containing numerous
vacuoles. Alveolar macrophages composed 95% ± 2% of the
BALF differential leukocyte count. All patients were negative
for C-reactive protein, conﬁrming lack of inﬂammation.
HCMV Immunoglobulin G (IgG) Serotyping of Donors
HCMV-speciﬁc IgG was assessed in patients’ serum specimens
by the Capita Cytomegalovirus IgG enzyme-linked immuno-
sorbent assay (ELISA) kit (Trinity Biotech) according to the
manufacturer’s instructions.
HCMV Immunoglobulin M (IgM) Serotyping of Donors
Donor serum specimens were tested using the Liaison CMV
IgM II chemiluminescence immunoassay (DiaSorin) for the
semiquantitative determination of speciﬁc IgM antibodies to
HCMV in human serum or plasma samples, according to the
manufacturer’s protocol.
Polymerase Chain Reaction (PCR) Analysis to Detect DNA
Viremia
Nucleic acid extractions from serum specimens were performed
on the automated BioRobot MDx extractor, using the One-for-
All kit. CMV RNA was quantiﬁed relative to the GAPDH
housekeeping gene, using the primers 5′-TGCCGGGTGGCG
AGTACCCTGT-3′ ( forward) and 5′-CAGTTCCGAGAGC
ACCGAGACG-3′ (reverse), with the probe 5′-[FAM]ATA
CAGCGTCACGCTAG[MGB]-3′. The following PCR parame-
ters were used: for the reverse transcription (RT) step, 50°C for
3 minutes, followed by denaturation at 95°C for 3 minutes; and
for the PCR step, 50 cycles at 95°C for 8 seconds and 58°C for 60
seconds. The samples were analyzed on the Rotor-Gene cycler.
RT–Quantitative PCR (qPCR) Analysis of IE Expression in
Alveolar Macrophages
Puriﬁed alveolar macrophages were lysed directly in Trizol (In-
vitrogen), and RNA was isolated using a micro RNA puriﬁca-
tion kit (Qiagen). RNA was quantiﬁed relative to the GAPDH
housekeeping gene, using the following primers and probes: for
IE, primers CAAGAACTCAGCCTTCCCTAAGAC and TGA
GGCAAGTTCTCGAATGC, with the probe [FAM]CCAAT
GGCTGCAGTCAGGCCATG[TAM]; for GAPDH, primers
GGAAGCTTGTCATCAATG and CCCCACTTGATTTTG
GAG, with the probe [JOE]ATCACCATCTTCCAGGAGCG
AG[BHQ1]; and for UL138, primers 5′-CGCTGTTTCTCT
GGTTAG and 5′-CAGACGATACCGTTTCTC, with the probe
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CCGACGACGAAGACGATGAAC[Cy5]. The following PCR
parameters were used: for the RT step, 50°C for 20 minutes, fol-
lowed by heat-based inactivation at 95°C for 5 minutes; and for
the PCR step, 50 cycles at 95°C for 15 seconds and 60°C for 45
seconds. The samples were analyzed on an ABI Real-Time 7500
machine.
ELISA of Tumor Necrosis Factor α (TNF-α) Levels
BALF ﬂuid was tested for levels of TNF-α, using the RND Sys-
tems ELISA kit according to the manufacturer’s protocol.
Coculture of Alveolar Macrophages and Fibroblasts
Puriﬁed alveolar macrophages (5 × 105 macrophages/well) were
cultured in a 24-well plate overnight before overlaying with ﬁ-
broblasts (1 × 105 macrophages/well). After 1 week, superna-
tants were transferred onto fresh human foreskin ﬁbroblasts
to quantify virus levels in the supernatant. After 3 weeks, the
cells were ﬁxed in 70% ethanol and stained for IE by immuno-
ﬂuorescence as previously described [19].
RESULTS
Alveolar Macrophages Are Permissive to HCMV Lytic Infection
A strong link between the permissiveness of cells to in vitro in-
fection with HCMV and their ability to reactivate latent virus
has previously been established [2, 3]. We therefore assessed
whether in vivo–differentiated alveolar macrophages could sup-
port full HCMV lytic infection. Although it was demonstrated
that alveolar macrophages matured in vitro were permissive to
HCMV infection [13, 15, 16], in vivo–differentiated alveolar
macrophages have not, to our knowledge, been tested. Alveolar
macrophages were harvested to 95% purity, as assessed by dif-
ferential cell counts, from the BALF of 10 donors (Figure 1A).
After adherence to plastic, cells were infected at a multiplicity of
infection of 5 with TB40E-IE-YFP virus, which expresses YFP-
tagged IE86 and allows live detection of virus infection. Fig-
ure 1B shows that, 24 hours after infection with virus, IE protein
was detectable in the nuclei of infected macrophages. Further-
more, supernatants taken from the macrophages 1 week after
the start of HCMV infection showed virus transfer onto fresh
ﬁbroblasts (Figure 1C). Therefore, in vivo–differentiated al-
veolar macrophages are fully permissive to HCMV infection
ex vivo.
Alveolar Macrophages From Seropositive Individuals Are Sites
of Viral IE Gene Expression
In vitro infection of in vivo–differentiated macrophages clearly
demonstrated that these cells were permissive to HCMV infec-
tion, suggesting that these differentiated macrophages may also be
sites of reactivation in vivo. To test whether in vivo–differentiated
macrophages express viral IE genes, serum specimens and alve-
olar macrophages were isolated from 10 donors for analysis.
Figure 1. Alveolar macrophages ex vivo from individuals are permissive to lytic human cytomegalovirus (HCMV) infection. A, Representative photomi-
crograph (original magniﬁcation ×40) of a typical cytospin preparation of freshly isolated human alveolar macrophages stained with modiﬁed Wright stain.
Alveolar macrophages were identiﬁed by their large dark nuclei and abundant pale, granular cytoplasm containing numerous vacuoles. Alveolar macro-
phages typically constitute >95% of the differential leukocyte count in bronchoalveolar lavage ﬂuid. B, Isolated macrophages were adhered to plastic and
then infected with the TB40E-IE-YFP strain of HCMV at a multiplicity of infection of 5. After 24 hours, some cells were counterstained with Hoechst stain to
detect nuclei. C, Alternatively, following infection of the macrophages with TB40E-IE-YFP virus, cells were washed and left for 1 week, and the supernatant
was collected and transferred onto fresh ﬁbroblasts. Abbreviation: IE, immediate early.
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The serostatus (ie, the presence of HCMV-speciﬁc IgG) of each
donor was assessed using ELISA. Figure 2A shows that 5 of 10
donors were seropositive.
Next, the expression of viral IE genes in alveolar macrophages
from seropositive carriers was assessed using sensitive RT-
qPCR. Figure 2B shows that all alveolar macrophages from sero-
positive donors were also positive for viral IE gene expression
and that, as predicted, only seropositive donors showed viral
gene expression. To conﬁrm that this ability to detect viral IE
RNAs in alveolar macrophages was not due to any ongoing
HCMV viremia in the donor, all donors were tested directly
for HCMV viremia, using 2 independent assays. HCMV-speciﬁc
IgM levels in serum specimens were assessed. As hypothesized,
HCMV-seronegative donors were also negative for HCMV-
speciﬁc IgG (Table 1), and, with the exception of one donor
(donor 7), none of the HCMV-positive donors were positive
for HCMV-speciﬁc IgM or viral genome in blood. In contrast,
donor 7, who presented with elevated levels of IgM antibodies
to HCMV also had a blood specimen with a positive PCR result,
arguing that this donor was likely viremic.
Collectively, these results provide clear evidence that in vivo–
differentiated macrophages obtained from seropositive donors
who show no signs of HCMV disease and are not viremic are
routinely positive for viral IE expression, arguing that these
are sites of HCMV IE gene reactivation in vivo.
As it was crucial to determine the inﬂammatory status of
these individuals, further tests were performed to detect mark-
ers of inﬂammation both systemically (by the presence of C-
reactive protein), as well as in the local microenvironment (by
the presence of TNF-α). Table 2 shows that the tested individ-
uals were not positive for C-reactive protein and that the BALF
did not contain detectable levels of TNF-α when assessed by
ELISA. These data suggest that any virus present in the alveolar
macrophages in these patients was not due to a nonspeciﬁc in-
ﬂammatory induction but was rather a naturally occurring reac-
tivation event.
Figure 2. Alveolar macrophages from seropositive individuals express immediate early gene (IE) messenger RNA (mRNA). A, Serum specimens from 10
donor patients (P) were tested for the presence of IE immunoglobulin G (IgG) by enzyme-linked immunosorbent assay (ELISA). B, Alveolar macrophages were
isolated directly ex vivo from the same patients and harvested for reverse-transcription quantitative polymerase chain reaction (PCR) analysis for the pres-
ence of human cytomegalovirus (HCMV) IE mRNA. A blood specimen from each patient was also assessed by PCR for the presence of HCMV DNA, to
determine whether viremia was present, and for the presence of IgM. These data and the data from panels A and B are summarized in Table 1.
Table 1. Alveolar Macrophages From Seropositive Individuals Express Immediate Early Gene (IE) Messenger RNA
Patient IE RNA IgG IgM DNA, by PCR
1 Not detected Not detected Not detected Not detected
2 Not detected Not detected ND Not detected
3 Not detected Not detected Not detected Not detected
4 Not detected Not detected Not detected Not detected
5 Not detected Not detected Not detected Not detected
6 Detected Detected ND Not detected
7 Detected Detected Detected 9.79 × 104 copies/mL
8 Detected Detected Not detected Not detected
9 Detected Detected Not detected Not detected
10 Detected Detected Not detected Not detected
Abbreviations: IgG, immunoglobulin G; IgM, immunoglobulin M; ND, not done; PCR, polymerase chain reaction.
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In Vivo–Differentiated Alveolar Macrophages Are Sites of
HCMV Virion Production
It is known that naturally latent monocytes can be differentiated
to allow reactivation of viral IE gene expression but without
subsequent viral gene expression or production of virions [2,
3, 7–11]. Similarly, a number of in vitro studies have demon-
strated that several cell types can be abortively infected with
HCMV; they support IE gene expression but not full virion pro-
duction [2, 3]. Therefore, 2 donors, one seronegative and the
other seropositive, were further analyzed to determine whether
alveolar macrophages were natural sites of full virus reactivation
and virion production.
We and others have previously shown that latent infection in
healthy seropositive virus carriers can be assessed by the anal-
ysis of peripheral monocytes for HCMV lytic gene expression
[2]. To ensure that the seropositive donor was latently infected,
CD14+ monocytes were isolated from blood and analyzed for
the standard hallmarks of latency: the presence of latent tran-
scripts and the absence of lytic gene transcription. Figure 3A
shows that CD14+ cells isolated from venous blood of the se-
ropositive donor expressed the latency-associated transcript
UL138 in the absence of expression of the lytic IE gene. We
did not observe viral gene expression in monocytes from the se-
ronegative donor. Alveolar macrophages from both donors were
stained for detection of IE; IE expression was detectable in a few
cells from the seropositive donor (Figure 3B) but in no cells
from the seronegative donor (data not shown).
To determine whether alveolar macrophages are sites of reac-
tivation of full virus production, they were cocultured on indica-
tor ﬁbroblasts. After 3 weeks of coculture, the ﬁbroblasts were
ﬁxed and stained for detection of infection foci where IE was
being expressed. Figure 4A shows that foci of infection were clear-
ly identiﬁable as areas of swollen cells within the ﬁbroblast mono-
layer. Figure 4B shows that less than one in a million alveolar
macrophages from seropositive individuals are productive for
viral spread in vitro. Finally, to demonstrate that virions were
being released into the supernatant, the supernatants were col-
lected and transferred onto fresh ﬁbroblasts, and the numbers
of IE-expressing cells were enumerated over time (Figure 4C).
Collectively, these are the ﬁrst data to show that alveolar mac-
rophages from donors who are seropositive for HCMV but not
viremic are fully competent sites of HCMV reactivation.
DISCUSSION
The extent to which HCMV reactivation occurs in seropositive
healthy carriers is uncertain. One hypothesis is that viral reac-
tivation occurs at the molecular level routinely in healthy carri-
ers but that dissemination of virus from these reactivation
events is prevented by immune competence.
It has been postulated that suchmolecular reactivation of latent
virus in vivo, in healthy carriers, results from the differentiation of
Figure 3. Monocytes ex vivo from a human cytomegalovirus (HCMV)-seropositive patient transcribe the HCMV latency gene UL138, and alveolar macro-
phages from the same donor express the HCMV lytic immediate early gene (IE) protein. Donors were tested for systemic inﬂammation (as revealed by the
presence of C-reactive protein) and local bronchoalveolar ﬂuid (BALF) inﬂammation (by means of enzyme-linked immunosorbent assay [ELISA] speciﬁc for
tumor necrosis factor α [TNF-α]). A positive control for the ELISAwas supernatant from monocyte-derived dendritic cells (DCs) shown in Table 2. A, Monocytes
were isolated from venous blood and harvested for reverse-transcription quantitative polymerase chain reaction analysis. B, Isolated alveolar macrophages
were cytospun and then ﬁxed and stained for detection of the HCMV lytic antigen, IE. Cells were counterstained with Hoechst stain to detect nuclei.
Table 2. Results of Tests for Detection of the Inﬂammation
Markers Tumor Necrosis Factor α (TNF-α) and C-reactive Protein,
by Human Cytomegalovirus Serostatus
Inflammation
Marker
Positive
Control Seronegative Seropositive
TNF-α, pg/mL 424 ± 21 Undetectable Undetectable
C-reactive protein NA Negative Negative
Abbreviation: NA, not applicable.
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myeloid progenitor cells to macrophages and DCs [2,3,7–9,11,17].
However, this hypothesis is largely based on the ex vivo differ-
entiation of myeloid progenitors. Previous work demonstrated
that differentiated but immature myeloid DCs from healthy se-
ropositive HCMV carriers are sites of reactivation of HCMV IE
gene expression in vivo but that reactivation of infectious virus
required additional inﬂammatory cytokine treatment ex vivo
[12]. Our results provide direct evidence that in vivo terminally
differentiated alveolar macrophages are sites of full HCMV re-
activation in virus carriers who do not show signs of HCMV
disease, viremia, or inﬂammation either systematically or in
the macrophage microenvironment.
Consistent with the view that differentiated macrophages
could represent a supportive environment for productive
HCMV infection, monocyte-derived macrophages are fully per-
missive to HCMV infection [13, 15, 16]. These ﬁndings are con-
sistent with previous data that demonstrated that macrophages
are sites of virus infections in individuals with acute HCMV dis-
ease [20]. Indeed, it has been demonstrated that the lung is
important for reactivation and disease progression during
HCMV infection [21]. Whether the IE expression observed
in alveolar macrophages in this study results from de novo
HCMV infection produced from other undeﬁned cells follow-
ing a reactivation event or whether it results from the reactiva-
tion of HCMV in the alveolar macrophages directly remains to
be established. However, none of the donors exhibited signs of
viremia or inﬂammation, suggesting that de novo infection of
the alveolar macrophages was unlikely. Furthermore, there is a
body of evidence from natural and experimental latent systems
that shows that differentiation of myeloid progenitors into mac-
rophage-like cells or DCs is an established mechanism for reac-
tivation [2, 3, 7–9, 11, 17]. Establishment of HCMV latency can
cause partial differentiation of monocytes [22, 23], and,
although analyzed in an experimental latency model by using
monocytes grown in differentiation cytokines and hence likely
already partially differentiated, Noriega et al [24] have recently
shown that latent infection itself can drive differentiation to a
macrophage-like phenotype, in itself, aiding reactivation of
virus. Thus, it seems likely that the observations presented
here represent in vivo reactivation events in the myeloid lineage
culminating in virus release from macrophages.
Our observations that in vivo–differentiated macrophages
support the reactivation of latent virus also provide strong sup-
port for the analysis of experimental latency models, which is
Figure 4. Alveolar macrophages isolated from human cytomegalovirus (HCMV)-seropositive donors support HCMV production and viral spread. A, Al-
veolar macrophages were cocultured with indicator ﬁbroblasts and stained for immediate early gene (IE) by immune ﬂuorescence. Light microscopy (left) and
ﬂuorescence (right) image of ﬁbroblasts are shown; the green nuclei indicate IE-positive cells (arrow). B and C, The number of IE-positive foci were quan-
titated (B), and supernatants collected after coculture were transferred onto fresh monolayers of fresh human foreskin ﬁbroblasts, with the number of IE-
positive cells quantitated 24 hours after transfer (C).
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underway in a number of laboratories, to understand the mech-
anisms essential for the maintenance of latent HCMV and its
subsequent reactivation in the cells of the myeloid lineage
and, thus, validate proposed clinical and therapeutic applica-
tions [25]. One caveat is that the myeloid lineage may not be
the only site of HCMV latency and reactivation [26]. Therefore,
similar studies of other cells, such as neural cells and their pro-
genitors, may be similarly informative.
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